Purdue Pharma

Executive Summary

Purdue Pharma, once synonymous with the opioid crisis via OxyContin, has restructured post-bankruptcy as a public benefit company focused on developing medications for pain and addiction. The company is now private and in Phase 1 stage, with a pipeline targeting non-opioid pain treatments and opioid use disorder therapies. Despite its past, Purdue is leveraging its expertise to address the crisis it helped create, but faces significant reputational and regulatory hurdles. The company's ability to advance its pipeline while navigating ongoing litigation and settlement obligations will be critical. With limited public data, conviction is tempered by execution risk and competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Clinical data readout for non-opioid pain candidate50% success
• TBDFinal court approval of bankruptcy restructuring plan90% success
• Q4 2026New partnership or licensing deal for addiction pipeline30% success